Recently Featured

Gilead Projects 6% HIV Sales Growth in 2026, Targeting $800M for Yeztugo

February 17, 2026
Gilead Sciences has announced an expected 6% growth in its HIV sales by 2026, driven significantly by the anticipated performance of its new drug, Yeztugo, which is projected to reach $800 million in sales. This forecast indicates a remarkable year-over-year growth of 433% for Yeztugo, reflecting the company’s confidence in the drug’s market potential and…

FDA Refuses to Review Moderna’s mRNA Flu Vaccine

February 17, 2026
The U.S. Food and Drug Administration (FDA) has declined to review Moderna’s application for its mRNA-based influenza vaccine, a significant setback for the biotech company. This decision, articulated by Vinay Prasad, a prominent figure within the FDA’s vaccine division, has raised eyebrows within the pharmaceutical community, particularly as Moderna asserts that the ruling contradicts previous…

J&J’s Tremfya Roars into 2026 with Massive TV Ad Spend, Trailed by AbbVie’s Rinvoq and Skyrizi

February 17, 2026
Johnson & Johnson’s Tremfya is set to dominate the television advertising landscape in 2026, with a significant investment that starkly contrasts the anticipated decline in pharma spending on traditional TV ads. This strategic move indicates J&J’s commitment to maintaining Tremfya’s market presence amidst evolving advertising trends. As competitors like AbbVie prepare to launch their own…

GSK and Teva Resolve Prolonged Coreg ‘Skinny Label’ Dispute

February 16, 2026
Following a more than decade-long legal back-and-forth over the generic drug carveout practice known as “skinny” labeling, GSK and Teva have put their dispute to bed, new court documents show. The resolution of this case marks a significant milestone in the ongoing dialogue surrounding the legality and application of skinny labels, which allow generic manufacturers…

Ongoing Cases